Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot-Assisted lung biopsy gets a Real-Time check: could boost accuracy and genetic testing

NCT ID NCT07685977

Diagnosis Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether adding rapid onsite evaluation (ROSE) during robotic-assisted bronchoscopy improves the diagnosis of peripheral lung lesions. ROSE lets doctors check biopsy samples immediately under a microscope to confirm they contain enough tissue. The study also looks at whether samples are adequate for next-generation sequencing, which guides personalized treatment. About 400 adults undergoing robotic bronchoscopy for a lung lesion will be randomly assigned to receive ROSE or not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could make lung biopsies more accurate and reduce the need for repeat procedures, while ensuring enough tissue is collected for genetic testing.
What could go wrong
The trial is still recruiting and results are not yet available. The benefit of rapid onsite evaluation may vary by lesion type or operator experience, and it may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years of age at time of bronchoscopy * Undergoing robotic assisted bronchoscopy to biopsy a pulmonary lesion Exclusion Criteria: * Declines to participate or inability to provide informed consent. * Clinician determination that the use of ROSE is required or contraindicated for the optimal care of an individual patient * Patient enrolled in another trial that requires ROSE for PPL biopsy * Patient previously consented for this trial * Pregnant or incarcerated patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral pulmonary lesions (PPLS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral pulmonary lesions (PPLS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts, 01805, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina, 27154, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.